首页> 中文期刊> 《海南医学》 >西替利嗪治疗轻中度哮喘患儿急性发作的疗效分析

西替利嗪治疗轻中度哮喘患儿急性发作的疗效分析

         

摘要

Objective To observe the clinical effect of cetirizine in the treatment of acute attack of asthma of mild to moderate degree in children. Methods Ninety children with acute attack of asthma of mild to moderate degree were randomly divided into the study group and the control group, with 45 cases in each group. The control group was given placebo orally, and the study group was given cetirizine, 2.5-5 mg for 2-5 years old children and 10 mg for 6-11 years old children, once a day, 5 days for a treatment course. Results The total effective rate of the study group was 91.1%, significantly higher than 73.3% in the control group (P<0.05). The two groups were improved in the clinical symptoms and signs of total score and FEV1/FVC and PEFR after treatment (P<0.05), and the study group has significantly lower scores of clinical symptoms and significantly higher FEV1/FVC and PEFR than the control group (P<0.05). There was no serious adverse reactions occurred. Conclusion The clinical effect of cetirizine for treating acute attack of asthma of mild to moderate degree in children is satisfactory and safe, which is worthy of clinical use.%目的 观察西替利嗪治疗儿童轻中度哮喘急性发作的临床疗效.方法 90例轻中度哮喘急性发作患儿随机分为观察组和对照组,各45例,两组均给予常规治疗,对照组给予安慰剂,观察组予西替利嗪口服,2~5岁2.5~5 mg,6~11岁10 mg,1次/d,疗程5d.结果 观察组有效率为91.1%,明显高于对照组的73.3%,差异有统计学意义(P<0.05);治疗后两组症状评分和肺功能指标FEV1/FVC、PEFR均有明显改善(P<0.05),且观察组症状评分低于对照组,肺功能指标FEV1/FVC和PEFR高于对照组,差异有统计学意义(P<0.05);两组治疗过程中均未发生明显不良反应.结论 西替利嗪治疗儿童轻中度哮喘急性发作疗效显著,不良反应少,值得在临床推广.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号